PRKG2-AS1: A Potential Drug Target and Biomarker (G101928942)

Target Name: PRKG2-AS1

NCBI ID: G101928942

PRKG2-AS1

Other Name(s): PRKG2 antisense RNA 1

PRKG2-AS1: A Potential Drug Target and Biomarker

PRKG2 (PRKG2 gene) is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. One of its functions is to regulate the activity of PRKG2-AS1, a protein that is known to interact with the RNA polymerase II (RNA-P2) complex. The study of PRKG2-AS1 has significant implications for the development of new drugs and therapies.

The PRKG2 gene is a member of the PRKG2 family, which is characterized by the presence of a specific N-terminal region that is involved in the formation of RNA structures. PRKG2-AS1 is a 24.1 kDa protein that is composed of 196 amino acid residues. It consists of a N-terminal region of 13 amino acids, a catalytic domain of 21 amino acids, and a C-terminal region of 42 amino acids.

PRKG2-AS1 functions as a negative regulator of PRKG2, by binding to its N-terminal region and preventing it from forming a stable RNA structure. This interaction between PRKG2 and PRKG2-AS1 is critical for the regulation of cellular processes such as cell growth, apoptosis, and transcriptional regulation.

The study of PRKG2-AS1 has led to the identification of several potential drug targets. One of the most promising targets is the inhibition of PRKG2-AS1, which has been shown to have therapeutic potential in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, PRKG2-AS1 has been shown to play a role in the regulation of cell cycle progression and the execution of the apoptosis program. It has also been shown to be involved in the regulation of angiogenesis, a process that is critical for the development of new blood vessels that can supply tumors with oxygen and nutrients.

In neurodegenerative diseases, PRKG2-AS1 has been shown to play a role in the regulation of synaptic plasticity, a process that is responsible for the formation and strengthening of neural connections. It has also been shown to be involved in the regulation of inflammation, a process that is critical for the development of neurodegenerative diseases.

In autoimmune disorders, PRKG2-AS1 has been shown to play a role in the regulation of immune cell function and the regulation of inflammation. It has also been shown to be involved in the regulation of stem cell proliferation, a process that is critical for the development of autoimmune disorders.

The identification of PRKG2-AS1 as a potential drug target has led to a significant increase in the number of studies aimed at its characterization and the development of new therapies. Although more research is needed to fully understand its functions and the potential therapeutic benefits of PRKG2-AS1, its study has significant implications for the development of new drugs and therapies that can treat a wide range of diseases.

In conclusion, PRKG2-AS1 is a non-coding RNA molecule that plays a critical role in various cellular processes. Its interaction with the RNA polymerase II (RNA-P2) complex and its functions as a negative regulator of PRKG2 have significant implications for the development of new drugs and therapies. Further research is needed to fully understand its functions and the potential therapeutic benefits of PRKG2-AS1.

Protein Name: PRKG2 Antisense RNA 1

The "PRKG2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRKG2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets